Drug Database
PR

prasterone (Mylis)

✓ Approved

Merck & Co. · AR · 小分子

什么是 prasterone?

prasterone 是一种小分子,由Merck & Co.研发。该药已获批,用于治疗相关适应症。

药物档案

商品名Mylis
公司Merck & Co.
药物类别小分子
分子靶点AR
状态Approved

作用机制

分子靶点

prasterone 作用于 1 个分子靶点:

ARandrogen receptor (DHTR, AR8)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

prasterone 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Surgical and medical proceduresLabour induction✓ Approved

相关研究文献

PubMedMicroscopy (Oxford, England)2026-11-17

Correlative Microstructural and Elemental Analysis of Sika Deer Feces Using Resin-Embedded Cross-Sectional Polishing and SEM-EDS.

Tsuda Asako A, Takagi Tomoko T, Toyooka Kiminori K, Nagata Noriko N

Traditional methods for investigating the diets of wild animals often depend on conventional approaches, including optical microscopy, and involve processing steps such as the washing and sieving fecal residues, which may alter or disperse the residues' original spatial configuration and compromise the preservation of detailed residue structures. Furthermore, DNA-based analyses generally require the disruption of fecal samples during sample processing, making it difficult to preserve the original morphology. Conversely, using resin-embedding techniques, conventional to electron microscopy, avoids this limitation, preserving the original shape and spatial configuration of fecal specimens and enabling a comprehensive analysis of fecal residues. To investigate the potential applicability of this approach to wildlife dietary analysis, we combined resin-embedded cross-sectional polishing and scanning electron microscopy for biological samples (bioCP-SEM) with energy-dispersive X-ray spectroscopy (EDS) to examine the morphology and elemental composition of fecal residues. As a model case, we analyzed fecal samples from sika deer (Cervus nippon) collected in Akaya, a mountainous area in Gunma Prefecture, and Nara Park, where deer routinely consume sika-senbei (deer crackers) as supplementary food. The results demonstrated that bioCP-SEM combined with EDS enabled the characterization of fecal residues while retaining information regarding their original shape and spatial configuration. Differences in the morphological and elemental characteristics of fecal residues were also found between two sites. This approach may complement conventional analytical methods and expand the range of information available for wildlife dietary analysis. When integrated with other analytical methods, it may contribute to a more comprehensive understanding of wildlife ecology and management.

PMID 43045667
阅读全文 →
PubMedHuman reproduction open2026-11-17

The management of endometriosis in adolescents and young adults: a systematic review.

Blyth Ursula U, Maslej Luba L, Bennett George G, Smith Carolyn C et al.

What evidence-based strategies are used in the treatment of endometriosis-associated symptoms in adolescents and young adults? The use of hormonal therapies and surgery was associated with improvements in pain symptoms in most studies; however, the certainty of evidence was very low, meaning that the true impact of these treatments remains uncertain. Endometriosis is a chronic condition estimated to affect 1 in 10 women, with symptoms commonly present during adolescence. Current management strategies for endometriosis include analgesia, hormonal suppression, and surgery, as well as non-pharmacological measures. This is a systematic review of the literature. Six databases (CINAHL, Cochrane Central Database of Controlled Trials, EMBASE, MEDLINE, PsychInfo, and Web of Science Core Collection) were searched from inception to May 2026. Search terms were related to endometriosis combined with terms regarding management and the adolescent age group. Eligible studies included participants aged under 24 years with endometriosis and reported on outcomes in the management of endometriosis-associated symptoms. Only studies with full texts or data available in English were included. Screening and data extraction were performed independently and in duplicate by two authors. Key outcomes included pain, quality of life, recurrence, and side effects. Data were reported narratively. Risk of bias was assessed according to study design (ROB2, NOS, and JBI tools) and quality of evidence with the GRADE system. The search identified 14 376 records, of which 333 full texts were assessed for eligibility, and 23 studies, with a combined total of 1561 participants, were included. There were two randomised controlled trials, one single-arm open-label interventional study, eleven cohort studies, and nine case series. Five studies investigated hormonal treatments, one other study assessed other pharmacological treatments, sixteen studies assessed surgical management with or without hormonal treatment, and one study investigated non-pharmacological treatments. Most studies reported improvements in pain symptoms; however, there was heterogeneity in study design, length of follow-up, and outcome measures. There is limited evidence in this age group. Most studies had a moderate risk of bias, and the certainty of evidence was very low. The very low certainty of evidence limits the ability to draw inferences from the data. More high-quality research is essential to understand the effectiveness of current treatments and identify how they should be tailored for this age group. No specific external or departmental funding was received for this systematic review. C.M.B. declares research grants from US DoD, NIH, EU Horizon 2020, Bayer AG, Aspira Ltd, Exeltis Ltd, Proteomics Inc, and Serac Healthcare Ltd, and consulting fees from Gedeon Richter, Theramex, Gesynta, and Roche (all paid to institution). C.M.B. is Chair of the ESHRE Endometriosis Guideline Group and a member of the NICE Endometriosis Guideline Group (unpaid). S.A.M. declares research grants (paid to institution) from AbbVie and the Marriot Family Foundations, received honoraria from the University of Kansas Medical Center and received travel support from LIDEA Registry, Taiwan Endometriosis Society, SEUD, Japan Endometriosis Society, NASEM, Endometriosis Foundation of America, Gedeon Richter, WES, New York Academy of Sciences, and Asian Conference on Endometriosis. S.A.M. is Field Chief Editor for Frontiers in Reproductive Health (personal fee) and is an advisory board member for the LIDEA Registry (personal fee) and has unpaid roles with Human Reproduction Statistical Advisory Board and the NextGen Jane Advisory Board, the Society for Women's Health Research, WERF, WES, ASRM, and ESHRE. K.V. reports research grants from the NIHR, NIH, UKRI, Medical Research Foundation, and EU IMI-2, consulting fees from Gesynta and Reckitts, and speakers' fees from Reckitts, Organon, Gedeon Richter, and Eli Lilly (all payments to institution). K.V. is a member of the Medical Advisory Panel of Endometriosis UK (unpaid). K.T.Z. declares research grants from the Gates Foundation, US DoD, NIH, EU Horizon 2020, Bayer AG, Aspira Ltd, Exeltis Ltd, Proteomics Inc, and Serac Healthcare Ltd and consulting fees from Apikal Ltd, Gedeon Richter, Roche, and LIDEA, (all paid to institution), and speaker's fees (paid to institution) from Rathlin Therapeutics and Camber Collective/Gates Foundation, received travel support for ESHRE 2025, SEUD 2024, EEC 2024, and LIDEA 2023, and is named on patent WO2024115891A1 relating to chronic pelvic pain treatment (NRG3), which is unrelated to the present manuscript. K.T.Z. is a board member of the World Endometriosis Foundation (unpaid). U.B., L.M., G.B., C.S., E.E., and P.M. declare no conflict of interest. Some of the above companies manufacture treatments discussed in this review. CRD420251018467.

PMID 43042315
阅读全文 →
PubMedBJOG : an international journal of obstetrics and gynaecology2026-11-08

Comparative Efficacy and Safety of Modern Treatment Modalities for Genitourinary Syndrome of Menopause: A Systematic Review and Network Meta-Analysis.

Randombage Prabath J S PJS, Akurugodagama Muthunu S MS

Genitourinary syndrome of menopause (GSM) is a chronic consequence of hypoestrogenism affecting vaginal, sexual and lower urinary tract health. Treatments include local vaginal oestrogen, intravaginal prasterone, oral ospemifene, hyaluronic acid preparations, moisturisers/lubricants and energy-based interventions, but comparative evidence is heterogeneous. To compare the relative efficacy and safety of contemporary GSM therapies using a systematic review and class-level network meta-analysis (NMA) of randomised controlled trials. MEDLINE/PubMed, Scopus, Cochrane CENTRAL, Web of Science, Google Scholar, ClinicalTrials.gov and WHO ICTRP were searched from inception to March 2026, with backward and forward citation searching. Randomised controlled trials enrolling postmenopausal women with symptomatic GSM or equivalent diagnoses. Two reviewers independently screened, extracted and linked reports from the same trial family and assessed RoB 2. The primary outcome was harmonised patient-reported symptom burden, using a prespecified hierarchy of global symptom score, most bothersome symptom, dyspareunia and vaginal dryness. A frequentist random-effects consistency NMA generated; Hedges g standardised mean differences (SMDs), 95% confidence intervals (CIs), prediction intervals and P-scores. Heterogeneity was estimated by REML; node splitting, a design-by-treatment interaction decomposition and sensitivity analyses assessed incoherence and influence. Confidence in all 21 network comparisons was evaluated with CINeMA using a validated percentage contribution matrix. Twenty-six efficacy publications represented 24 unique trial families and 4958 randomised participants after denominator adjudication. The primary symptom NMA included 15 trial families, seven nodes and 3415 participants. Versus placebo/sham/control, local vaginal oestrogen was the only class with a CI excluding the null (SMD 0.34, 95% CI 0.02-0.66). Estimates were imprecise for prasterone (0.37, -0.10 to 0.84), hyaluronic acid (0.31, -0.10 to 0.72), ospemifene (0.24, -0.38 to 0.87), moisturiser/lubricant (0.15, -0.37 to 0.67) and CO2 laser (0.03, -0.56 to 0.61). Heterogeneity remained material (τ2 = 0.097; I2 = 65.6%). Node splitting showed no statistically detectable local incoherence (all p ≥ 0.35) and the global design-by-treatment interaction decomposition was also non-significant (Q = 4.90, df = 3, p = 0.179). P-scores were similar for local oestrogen (0.704) and prasterone (0.704) and rankings were sensitivity-dependent. CINeMA confidence was low for local oestrogen versus placebo/sham/control and prasterone versus placebo/sham/control and very low for the remaining 19 network comparisons. Radiofrequency was not included in the primary symptom NMA because a hierarchy-compatible continuous symptom effect with extractable dispersion was unavailable. Overall RoB 2 was low for 2 trial families, some concerns for 11 and high for 11. Local vaginal oestrogen remains the best-supported benchmark for symptomatic GSM. Hyaluronic acid, prasterone and ospemifene have clinically relevant evidence, but cross-class estimates are imprecise and rankings are unstable. CO2 laser and radiofrequency should not be positioned as equivalent or superior first-line treatments on the available evidence. The data support individualised stepped care rather than a definitive treatment hierarchy. PROSPERO CRD420261332305.

PMID 43000041
阅读全文 →
PubMedMaturitas2026-11-08

Dehydroepiandrosterone in menopausal medicine: From adrenal aging to intracrinology and personalised therapy.

Parra-Armendaris Manuel M MM, Parra-Yagnam Francisca S FS, Simoncini Tommaso T

Dehydroepiandrosterone and its sulfate are the most abundant circulating steroids in women, yet they have no high-affinity nuclear receptor of their own. Their physiological role is that of a precursor pool from which active androgens and estrogens are generated locally, within peripheral target cells, through the tissue-specific expression of steroidogenic enzymes-the process Labrie termed intracrinology. After menopause, when ovarian estrogen secretion ceases, essentially all estrogens and a large fraction of androgens acting on peripheral tissues derive from the intracrine conversion of adrenal dehydroepiandrosterone. Because adrenal dehydroepiandrosterone production declines progressively from the third decade of life (adrenopause), the menopausal woman faces a dual hormonal deficit: ovarian and adrenal. PubMed/MEDLINE, Embase and the Cochrane Library were searched for randomised trials, meta-analyses, mechanistic and pharmacokinetic studies, and current society position statements on dehydroepiandrosterone and prasterone in menopausal women, supplemented by hand-searching of key reference lists. This narrative review develops the intracrine framework as the conceptual bridge between adrenal aging and clinical therapeutics and critically appraises the evidence for two very different therapeutic strategies. Oral dehydroepiandrosterone, despite decades of investigation and a biologically coherent rationale, has not demonstrated convincing benefit on menopausal symptoms, sexual function, mood, bone or quality of life in women with normal adrenal function, and current guidelines do not endorse it. By contrast, intravaginal prasterone (6.5 mg dehydroepiandrosterone) exploits intracrinology at the level of a single estrogen- and androgen-responsive organ, improving the signs and symptoms of the genitourinary syndrome of menopause and moderate to severe dyspareunia while leaving serum sex-steroid levels within the normal postmenopausal range; it is approved by the United States Food and Drug Administration and the European Medicines Agency and is increasingly incorporated into international recommendations. We summarise the comparative evidence against other menopausal therapies, review the safety signal, contrast the positions of the major societies, and outline how biomarker-guided, intracrine-informed precision medicine might define the future role of dehydroepiandrosterone. The dehydroepiandrosterone story is, ultimately, one about where in the body a hormone should be made-and acted upon.

PMID 42998568
阅读全文 →
PubMedBehavioural processes2026-11-05

Sex ratio allocation supports the Trivers-Willard hypothesis in Cervinae.

Lazar Petr P, Šárová Radka R, Pluháček Jan J

Adaptive secondary sex ratio allocation represents one of the most studied topics of behavioural ecology. Among many theories explaining this phenomenon, two are the most influential: Trivers-Willard hypothesis (TWH) and Local Resource Competition Model (LRCM). Despite many studies examining this topic, only a few of them focused on more than a single species. As natural history and social organisation among various species differ, different species might adapt different strategies in sex ratio adjustment. Therefore, we tested these hypotheses using data in five deer species born in six zoos - Père David's deer (Elaphurus davidianus, N = 377), elk (Cervus canadensis, N = 252), sika deer (Cervus nippon, N = 167), chital (Axis axis, N = 188) and reindeer (Rangifer tarandus, N = 371). We found that the overall secondary sex ratio did not differ from 1:1. In Cervinae, we found that the secondary sex ratio increased with increasing age of the mother corresponding with the TWH. On the other hand, in reindeer, we revealed the opposite results in line with LRCM. In addition, we found that in Père David's deer, and Vietnamese sika deer males were born earlier during the peak of the birth season than females. This result lends support to TWH as males born earlier could receive higher investment from mothers than those born later and this might affect their reproductive success in the future. Our study represents one of a few including several closely related mammalian species on this topic.

PMID 42988071
阅读全文 →
PubMedJournal of neurological surgery reports2026-11-04

Delayed Posterior Choroidal Artery Aneurysm Formation and Rupture in a Postsuperior Temporal Artery to Middle Cerebral Artery Bypass Moyamoya Disease Patient.

Hsu William Wei WW, Soliven Ryerson Emil Magdaleno Rosario REMR, Igarashi Yutaka Y, Kanaya Takahiro T et al.

Background Moyamoya disease is a rare vascular disease that presents with stenosis of the internal carotid artery accompanied by formation of abnormal, fragile blood vessels at the base of the brain. This pathology often presents with aneurysms, which may cause ischemic or hemorrhagic complications. We present a case of posterior choroidal artery aneurysm in a moyamoya disease patient that ruptured following a 6-year asymptomatic period after the patient received superior temporal artery to middle cerebral artery bypass. Observations A 57-year-old female Japanese patient who received superficial temporal artery to middle cerebral artery bypass for moyamoya disease presented to the Nippon Medical School Hospital emergency room for sudden loss of consciousness after a 6-year asymptomatic period following her bypass procedure. She was diagnosed with left subcortical hemorrhage with ventricular rupture and hydrocephalus associated with a left medial posterior choroidal artery aneurysm. This was then subsequently managed with bilateral ventricular drainage, clipping, spinal drainage, and finally lumbar-peritoneal shunt. Conclusion Our case demonstrates delayed aneurysm formation at the posterior choroidal artery even after bypass surgery. Our patient's 6-year silent period after her bypass surgery highlights the need for long-term surveillance after the immediate postoperative period even if the patient is asymptomatic due to the possibility of chronic cerebrovascular changes following bypass that may go undetected.

PMID 42979662
阅读全文 →

注册免费账户还可查看另外 2799 篇文献

免费注册查看全部文献 →

了解更多prasterone